MedKoo product information:

 Streptozocin

streptozocin is a methylnitrosourea antineoplastic antibiotic isolated from the bacterium Streptomyces achromogenes. Streptozocin alkylates DNA, forming inter-strand DNA cross-links and inhibiting DNA synthesis. Due to its glucose moiety, this agent is readily taken up by pancreatic beta cells, inducing diabetes mellitus at high concentrations. Unlike other nitrosoureas, streptozocin causes little myelosuppression. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

History

Streptozotocin was originally identified in the late 1950s as an antibiotic. The drug was discovered in a strain of the soil microbe Streptomyces achromogenes by scientists at the drug company Upjohn (now part of Pfizer) in Kalamazoo, Michigan. The soil sample in which the microbe turned up had been taken from Blue Rapids, Kansas, which can therefore be considered the birthplace of streptozotocin. Upjohn filed for patent protection for the drug in August 1958 and U.S. Patent 3,027,300 was granted in March 1962. In the mid-1960s streptozotocin was found to be selectively toxic to the beta cells of the pancreatic islets, the cells that normally regulate blood glucose levels by producing the hormone insulin. This suggested the drug's use as an animal model of diabetes, and as a medical treatment for cancers of the beta cells.In the 1960s and 1970s the National Cancer Institute investigated streptozotocin's use in cancer chemotherapy. Upjohn filed for FDA approval of streptozotocin as a treatment for pancreatic islet cell cancer in November 1976, and approval was granted in July 1982. The drug was subsequently marketed as Zanosar. Streptozotocin is now marketed by the generic drug company Sicor (Teva). (The above information was directly from: http://en.wikipedia.org/wiki/Streptozotocin).

DRUG DESCRIPTION

Each vial of ZANOSAR contains 1 g of the active ingredient streptozocin 2 -deoxy - 2 -[[(methylnitrosoamino)carbonyl]amino] - α(and β) - D - glucopyranose and 220 mg citric acid anhydrous. ZANOSAR is available as a sterile, pale yellow, freeze-dried preparation for intravenous administration. The pH was adjusted with sodium hydroxide. When reconstituted as directed, the pH of the solution will be between 3.5 and 4.5. Streptozocin is a synthetic antineoplastic agent that is chemically related to other nitrosoureas used in cancer chemotherapy. Streptozocin is an ivory-colored crystalline powder with a molecular weight of 265.2. It is very soluble in water or physiological saline and is soluble in alcohol.

CLINICAL PHARMACOLOGY

Streptozocin inhibits DNA synthesis in bacterial and mammalian cells. In bacterial cells, a specific interaction with cytosine moieties leads to degradation of DNA. The biochemical mechanism leading to mammalian cell death has not been definitely established; streptozocin inhibits cell proliferation at a considerably lower level than that needed to inhibit precursor incorporation into DNA or to inhibit several of the enzymes involved in DNA synthesis. Although streptozocin inhibits the progression of cells into mitosis, no specific phase of the cell cycle is particularly sensitive to its lethal effects. Streptozocin is active in the L1210 leukemic mouse over a fairly wide range of parenteral dosage schedules. In experiments in many animal species, streptozocin induced a diabetes that resembles human hyperglycemic nonketotic diabetes mellitus. This phenomenon, which has been extensively studied, appears to be mediated through a lowering of beta cell nicotinamide adenine dinucleotide (NAD) and consequent histopathologic alteration of pancreatic islet beta cells. The metabolism and the chemical dissociation of streptozocin that occurs under physiologic conditions has not been extensively studied. When administered intravenously to a variety of experimental animals, streptozocin disappears from the blood very rapidly. In all species tested, it was found to concentrate in the liver and kidney. As much as 20% of the drug (or metabolites containing an N-nitrosourea group) is metabolized and/or excreted by the kidney. Metabolic products have not yet been identified.

  1: Bartzatt R. Design of anticancer agents utilizing streptozocin for in silico optimization of properties and pattern recognition identification of group features. Open Med Chem J. 2008 Sep 2;2:81-6. PubMed PMID: 19662148; PubMed Central PMCID: PMC2709472.

2: Pari L, Murugan P. Changes in glycoprotein components in streptozotocin--nicotinamide induced type 2 diabetes: influence of tetrahydrocurcumin from Curcuma longa. Plant Foods Hum Nutr. 2007 Mar;62(1):25-9. Epub 2007 Jan 17. PubMed PMID: 17226069.

3: Moore AS, Kitchell BE. New chemotherapy agents in veterinary medicine. Vet Clin North Am Small Anim Pract. 2003 May;33(3):629-49, viii. Review. PubMed PMID: 12852240.

4: Kintzel PE. Anticancer drug-induced kidney disorders. Drug Saf. 2001 Jan;24(1):19-38. Review. PubMed PMID: 11219485.

5: Kinnamon KE, Poon BT, Hanson WL, Waits VB. Activity of anticancer compounds against Trypanosoma cruzi-infected mice. Am J Trop Med Hyg. 1998 Jun;58(6):804-6. PubMed PMID: 9660468.

6: Ali-Osman F, Giblin J, Dougherty D, Rosenblum ML. Application of in vivo and in vitro pharmacokinetics for physiologically relevant drug exposure in a human tumor clonogenic cell assay. Cancer Res. 1987 Jul 15;47(14):3718-24. PubMed PMID: 2954633.

7: Cantrell JE Jr, Green D, Schein PS. Antitumor activity and bone marrow toxicity of aminoglucose mustard anticancer agents in mice. Cancer Res. 1986 May;46(5):2340-3. PubMed PMID: 2938728.

8: Kramer RA, Boyd MR, Dees JH. Comparative nephrotoxicity of 1-(2-chloroethyl)-3-(trans-4-methylcyclohexyl)-1-nitrosourea (MeCCNU) and chlorozotocin: functional-structural correlations in the Fischer 344 rat. Toxicol Appl Pharmacol. 1986 Mar 15;82(3):540-50. PubMed PMID: 2937179.

9: Johnston TP, Montgomery JA. Relationship of structure to anticancer activity and toxicity of the nitrosoureas in animal systems. Cancer Treat Rep. 1986 Jan;70(1):13-30. Review. PubMed PMID: 2935250.

10: Niell HB, Soloway MS, Wood CA. Effect of concentration and time of drug exposure on clonal growth of murine bladder cancer. Urology. 1985 Mar;25(3):267-72. PubMed PMID: 2579500.

11: Yoshimori M, Tajiri H, Nakamura K, Ozaki H. [Chemotherapy of pancreatic cancer]. Gan To Kagaku Ryoho. 1985 Feb;12(2):227-34. Japanese. PubMed PMID: 3155930.

12: Byrne P, Tew K, Jemionek J, MacVittie T, Erickson L, Schein P. Cellular and molecular mechanisms of the bone marrow sparing effects of the glucose chloroethylnitrosourea chlorozotocin. Blood. 1984 Apr;63(4):759-67. PubMed PMID: 6322885.

13: Soloway AH, Brumbaugh RJ, Witiak DT. Carbinolamines and related structures--potential alkylating metabolites of clinically active anticancer drugs. J Theor Biol. 1983 Jun 7;102(3):361-73. PubMed PMID: 6225911.

14: Panasci L, Comis R, Ginsberg S, Kohn L, Fitzpatrick A, Rubert M, Scalzo T. Phase I trial of chlorozotocin: attempted amelioration of myelotoxicity by glucose administration. Cancer Treat Rep. 1981 Jul-Aug;65(7-8):647-50. PubMed PMID: 6454483.

15: Zimmerman SE, Smith FP, Schein PS. Chemotherapy of pancreatic carcinoma. Cancer. 1981 Mar 15;47(6 Suppl):1724-8. PubMed PMID: 6456058.

16: Bleiberg H, Rozencweig M, Kenis Y. [Anticancer therapy of carcinoid tumours (author's transl)]. Acta Gastroenterol Belg. 1981 Mar-Apr;44(3-4):145-52. French. PubMed PMID: 6457496.

17: Fiebig HH, Eisenbrand G, Zeller WJ, Zentgraf R. Anticancer activity of new nitrosoureas against Walder carcinosarcoma 256 and DMBA-induced mammary cancer of the rat. Oncology. 1980;37(3):177-83. PubMed PMID: 6444708.

18: Smulson ME, Schein P, Mullins DW Jr, Sudhakar S. A putative role for nicotinamide adenine dinucleotide-promoted nuclear protein modification in the antitumor activity of N-methyl-N-nitrosourea. Cancer Res. 1977 Sep;37(9):3006-12. PubMed PMID: 195715.

19: Schein PS, Panasci L, Woolley PV, Anderson T. Pharmacology of chlorozotocin Nsc-178248), a new nitrosourea antitumor agent. Cancer Treat Rep. 1976 Jun;60(6):801-5. PubMed PMID: 133756.

20: Horton J, Mittelman A, Taylor SG 3rd, Jurkowitz L, Bennett JM, Ezdinli E, Colsky J, Hanley JA. Phase II trials with procarbazine (NSC-77213), streptozotocin (NSC-85998), 6-THIOGUANINE (NSC-752), and CCNU (NSC-79037) in patients with metastatic cancer of the large bowel. Cancer Chemother Rep. 1975 Mar-Apr;59(2 Pt 1):333-40. PubMed PMID: 125147.

21: Anderson T, McMenamin MG, Schein PS. Chlorozotocin, 2-(3-(2-chloroethyl)-3-nitrosoureido)-D-glucopyranose, an antitumor agent with modified bone marrow toxicity. Cancer Res. 1975 Mar;35(3):761-5. PubMed PMID: 123170.

22: Johnston TP, McCaleb GS, Montgomery JA. Synthesis of chlorozotocin, the 2-chloroethyl analog of the anticancer antibiotic streptozotocin. J Med Chem. 1975 Jan;18(1):104-6. PubMed PMID: 122802.